Partnership to advance investigational amyloid PET imaging biomarker

A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.
According to a joint press release from Meilleur Technologies Inc. and PharmaLogic Holdings Corp., the latter will develop fluorine-18 [F18]NAV4694 for use in clinical trials at select United States-based radiopharmacies.
“We are delighted that the NAV4694 clinical and research program will be supported by PharmaLogic’s extensive PET manufacturing and dispensing expertise,”

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart